Association of the Promoter Methylation of Mitochondrial Transcription Factor A With Susceptibility to Metabolic Syndrome

Mohammad Hashemi [1,2,*]; Hamzeh Rezaei [2]; Mahmoud Ali Kaykhaei [3]; Mohsen Taheri [4]

[1]Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
[2]Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
[3]Department of Internal Medicine, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
[4]Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran

Corresponding author: Mohammad Hashemi, Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran. Tel/Fax: +98-5413235122, E-mail: mhd.hashemi@gmail.com; hashemim@zdmu.ac.ir

Background: It has been proposed that the patients with mitochondrial diseases usually manifest systemic metabolic disorders. The metabolic syndrome (MeS), a cluster of several metabolic disorders, is increasingly being recognized as a risk factor for type 2 diabetes (T2D) and cardiovascular disease.

Objectives: The aim of study was to investigate the possible association between promoter methylation of mitochondrial transcription factor A (TFAM) and MeS.

Patients and Methods: DNA was extracted from peripheral blood of 151 patients with and 149 without MeS.

Results: TFAM promoter methylation was evaluated by a nested methylation-specific PCR (nested MSP).

Conclusions: No association was found between TFAM promoter methylation and MeS. The present study suggests that the TFAM promoter methylation is not associated with risk of MeS.

Keywords: Metabolic Syndrome X; Mitochondrial Transcription Factor A; Diabetes Mellitus, Type 2 DM

1. Background

Metabolic syndrome (MeS) is described as a combination of clinical disorders that increase the risk of obesity (central adiposity), insulin resistance, glucose intolerance, dyslipidemia, non-alcoholic fatty liver disease and cardiovascular diseases including atherosclerosis, stroke and hypertension (1, 2). During the past decades the prevalence of metabolic syndrome is increasing dramatically worldwide, and is becoming an important health problem (3, 4). The etiology of MeS is unknown and is considered to be the result of interaction between genetic and environmental factors. Mitochondrial transcription factor A (TFAM) is involved in the maintenance of the mitochondrial genome. TFAM gene is mapped on chromosome 10q21.1. TFAM plays an important role in direct regulation of mitochondrial DNA (mtDNA) copy number, affecting transcription initiation and replication, which indicates that TFAM is essential for the maintenance of mtDNA (5). TFAM is a nuclear-encoded protein of 246 amino acids (25 kDa) with a mitochondrial targeting presequence of 42 amino acids (6). TFAM was initially recognized as a transcriptional activator of mitochondrial DNA (mtDNA) but latter, it was found to be crucial for mtDNA replication (7). Consequently, TFAM is consid-

ered a key regulator of mtDNA transcription and replication. Also, there are several lines of evidence proposing that TFAM regulates the transcription and replication of mtDNA in vivo. First, disruption of the TFAM gene in mice causes major cellular dysfunction, embryonic lethality, and mitochondrial diabetes resulting from mtDNA depletion and loss of oxidative phosphorylation capacity (5, 8). Second, TFAM levels are responsive to the amounts of mtDNA in the cell, since it is present in low amount in rho-zero cells lacking mtDNA (9). Third, differences in mitochondrial transcriptional activity and mtDNA synthesis, correlate with the relative amounts of TFAM (10, 11). Mitochondrial DNA (mtDNA) content dropped in an age-dependent manner and may be one of the causal factors in age-related type 2 diabetes (12). It has been suggested that age-related alterations of oxidative stress may affect mtDNA replication via regulating TFAM activity (12). It has been suggested that TFAM promoter methylation might play a role in the pathogenesis of insulin resistance. There is little information regarding the effect of TFAM promoter methylation on MeS.

2. Objectives

In the current study, we aimed to evaluate the associa-

---

tion between TFAM promoter methylation and metabolic syndrome in a sample of the Iranian population.

3. Patients and Methods

This case-control study was performed on 151 patients with and 149 without MeS. MeS was defined using the national cholesterol education program adult treatment panel III (NCEP ATP III) criteria (expert panel on Detection and Treatment of High Blood Cholesterol in Adults, 2001) as described previously (4, 13). Ethical approvals were obtained from Ethics Committee of Zahedan University of Medical Sciences, and informed consent was obtained from all individuals. data including weight, height, waist circumference, systolic and diastolic blood pressures; blood levels of glucose, triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol were collected as described previously (4, 13). Blood samples were collected in EDTA-containing tubes and genomic DNA was extracted using salting out method as described previously (14).

3.1. TFAM Promoter Methylation

DNA methylation of CpG dinucleotides affects the expression of many genes (15). The 2378 bp long human mtTFA promoter contains 67 CpG dinucleotides, the so-called CpG islands. The CpG sites have been known to be methylation sites during genomic imprinting and gene regulation. The DNA samples were treated with sodium bisulfite, which converts unmethylated C to U. However, once methylation occurs at C residues, they will resist the treatment. Bisulfite treatment of DNA was done as described previously (16). We developed a nested methylation-specific PCR (nested MSP) method for detection the promoter methylation of TFAM that increased MSP sensitivity. First-stage PCR primers in the nested MSP recognized a bisulfite-treated template but did not discriminate between methylated and unmethylated alleles. In the second stage, two pairs of primers are used; one pair of primers is specific for an unmethylated template, and the other pair is specific for a methylated template. The forward and reverse primers for the first stage were 5′-GTAAGTTGGAGGTTAGATTGAAAG -3′ and 5′-ATAAAATCTACATTCCAACCCC-3, respectively, producing a 963 bp amplicon that was used as template for the second PCR stage. The second stage was done as described by Gemma et al. (17). Primer sequences used to amplify an unmethylated product were 5′-TAATGGGTTTTATATAGATATATGG-3′ (sense) and 5′-CAAAAATAATAACAAAAAAAACAAA-3′ (antisense), and primer sequences for the methylated reaction were 5′-TTAATGGGTTTTATATAGATATACGG-3′ (sense) and 5′-AAAAATAATAACGAAAAAAAACGAA-3′ (antisense). The amplicon size was 102-bp.

Polymerase chain reaction (PCR) was performed using a commercially available PCR HotStart premix (AccuPower PCR HotStart PreMix; Bioneer Corp., Daejeon, Korea) according to the manufacturer's instructions. Briefly, 1 μL modified DNA, 1 μL each primer (10 pmol/mL), and 17 μL DNase-free water were added to AccuPower PCR PreMix.

The PCR cycling conditions were as follow; 95˚C for 10 minutes, and 35 cycles containing a 95˚C for 30 seconds, 57˚C for 30 seconds, and 72˚C for 30 seconds with a final extension at 72˚C for 10 minutes. The PCR products were visualized on 2% agarose gel containing ethidium bromide and photograph was taken (Figure 1).

3.2. Statistical Analysis

The differences between the variables were assessed by Chi-square test or T-tests. The association between genotypes and metabolic syndrome was assessed by computing the odds ratio (OR) and 95% confidence intervals (95% CI) from logistic regression analyses. P value less than 0.05 were considered as significant. All statistical analyses were performed using the SPSS (Statistical Package for the Social Sciences) software version18 (SPSS Inc, Chicago, IL).

4. Results

A total of 300 subjects including 151 MeS patients (50 males, 101 females; mean age: 41.98 ± 14.65 years) and 149 subjects without MeS (45 males, 104 females; mean age: 43.53 ± 15.96 years) were recruited in the study. There were no significant differences between the groups regarding gender (P=0.621) and age (P=0.382). Neither the overall chi-square comparison of patients with and without MeS nor the logistic regression analysis showed any association between TFAM promoter methylation and MES (Table 1).

Figure 1. Electrophoresis Pattern of Promoter Methylation Analysis of TFAM Using Nested MSP

Methylated and unmethylated primers amplify a 102-bp product.

Table 1. Frequency Distribution of the TFAM Promoter Methylation in Individuals With and Without MeS [a, b]

TFAM Promoter Methylation	MeS		OR (95%CI) [c]	P Value
	Yes	No		
MM	82 (54.3)	72 (48.3)	1.00	-
MU	24 (15.9)	38 (25.5)	0.55 (0.30-1.01)	0.070
UU	45 (29.8)	39 (26.2)	1.01 (0.59-1.73)	0.944
MU + UU	69 (45.7)	77 (51.7)	0.79 (0.50-1.23)	0.355

[a] Abbreviations: U, unmethylated; M, methylated
[b] Data are presented as No. (%)
[c] Adjusted for sex and age

5. Discussion

Mitochondria are involved in the regulation of energy metabolism and their defects are correlated with aging and a variety of diseases including cardiovascular diseases, neurological disorders, myopathies, muscle weakness and cancer (18). In the present study, we investigated the possible association between TFAM gene promoter methylation and MeS in a sample of the Iranian population. Our findings revealed that TFAM promoter methylation was not associated with MeS. It has been reported that increased production of ROS in adipocytes with mitochondrial dysfunction involved in the down-regulation of GLUT4 and impaired insulin sensitivity (19). Gemma et al. (17) suggested that promoter TFAM methylation might play a role in the pathogenesis of insulin resistance. Sookoian et al. (20) evaluated whether promoter methylation (epigenetic factors) of peroxisome proliferator–activated receptor c coactivator 1 alpha (PPARGC1A) and TFAM in the liver are associated with peripheral insulin resistance. In non-alcoholic fatty liver disease (NAFLD) patients, they found that methylation levels of PPARGC1A promoter were correlated with homeostatic model assessment-insulin resistance (HOMA-IR) and plasma fasting insulin levels, while TFAM promoter methylation was inversely associated with fasting insulin. Metabolic syndrome is a combination of risk factors for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) (21). These factors include hyperglycemia, high blood pressure, dyslipidemia primarily characterized by increased levels of triglyceride and low HDL-cholesterol and obesity (particularly with abdominal localization) (4). The prevalence of MeS varies worldwide and depends in part on lifestyle, sex, age and ethnicity (4, 22). In conclusion, our findings showed no association between TFAM promoter hypermethylation and MeS. Further studies with are required to validate our findings in different ethnicities.

Authors' contribution

Mohammad Hashemi, Study design, Data analysis and manuscript preparation; Hamzeh Rezaei, Experimental studies and final approval of the manuscript; Mahmoud-Ali Kaykhaei, Data collection and final approval of the manuscript; Mohsen Taheri, Data analysis and final approval of the manuscript.

References

1. Abete I, Goyenechea E, Zulet MA, Martinez JA. Obesity and metabolic syndrome: potential benefit from specific nutritional components. *Nutr Metab Cardiovasc Dis.* 2011;**21 Suppl 2**:B1–15.
2. Church T. Exercise in obesity, metabolic syndrome, and diabetes. *Prog Cardiovasc Dis.* 2011;**53**(6):412–8.
3. Azimi-Nezhad M, Herbeth B, Siest G, Dade S, Ndiaye NC, Esmaily H, et al. High prevalence of metabolic syndrome in Iran in comparison with France: what are the components that explain this? *Metab Syndr Relat Disord.* 2012;**10**(3):181–8.
4. Kordi-Tamandani DM, Hashemi M, Sharifi N, Kaykhaei MA, Torkamanzehi A. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome. *Mol Biol Rep.* 2012;**39**(2):937–43.
5. Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. *Nat Genet.* 1998;**18**(3):231–6.
6. Fisher RP, Clayton DA. A transcription factor required for promoter recognition by human mitochondrial RNA polymerase. Accurate initiation at the heavy- and light-strand promoters dissected and reconstituted in vitro. *J Biol Chem.* 1985;**260**(20):11330–8.
7. Clayton DA. Transcription and replication of mitochondrial DNA. *Hum Reprod.* 2000;**15 Suppl 2**:11–7.
8. Silva JP, Kohler M, Graff C, Oldfors A, Magnuson MA, Berggren PO, et al. Impaired insulin secretion and beta-cell loss in tissue-specific knockout mice with mitochondrial diabetes. *Nat Genet.* 2000;**26**(3):336–40.
9. Larsson NG, Oldfors A, Holme E, Clayton DA. Low levels of mitochondrial transcription factor A in mitochondrial DNA depletion. *Biochem Biophys Res Commun.* 1994;**200**(3):1374–81.
10. Gensler S, Weber K, Schmitt WE, Perez-Martos A, Enriquez JA, Montoya J, et al. Mechanism of mammalian mitochondrial DNA replication: import of mitochondrial transcription factor A into isolated mitochondria stimulates 7S DNA synthesis. *Nucleic Acids Res.* 2001;**29**(17):3657–63.
11. Montoya J, Perez-Martos A, Garstka HL, Wiesner RJ. Regulation of mitochondrial transcription by mitochondrial transcription factor A. *Mol Cell Biochem.* 1997;**174**(1-2):227–30.
12. Choi YS, Kim S, Pak YK. Mitochondrial transcription factor A (mtT-FA) and diabetes. *Diabetes Res Clin Pract.* 2001;**54 Suppl 2**:S3–9.
13. Hashemi M, Kordi-Tamandani DM, Sharifi N, Moazeni-Roodi A, Kaykhaei MA, Narouie B, et al. Serum paraoxonase and arylesterase activities in metabolic syndrome in Zahedan, southeast Iran. *Eur J Endocrinol.* 2011;**164**(2):219–22.
14. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM, et al. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. *Genet Mol Res.* 2010;**9**(1):333–9.
15. Wutz A, Smrzka OW, Schweifer N, Schellander K, Wagner EF, Barlow DP. Imprinted expression of the Igf2r gene depends on an intronic CpG island. *Nature.* 1997;**389**(6652):745–9.
16. Hashemi M, Rezaei H, Eskandari-Nasab E, Kaykhaei MA, Taheri M. Association of promoter methylation and 32-bp deletion of the PTEN gene with susceptibility to metabolic syndrome. *Mol Med Rep.* 2013;**7**(1):342–6.
17. Gemma C, Sookoian S, Dieuzeide G, Garcia SI, Gianotti TF, Gonzalez CD, et al. Methylation of TFAM gene promoter in peripheral white blood cells is associated with insulin resistance in adolescents. *Mol Genet Metab.* 2010;**100**(1):83–7.
18. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu Rev Genet.* 2005;**39**:359–407.
19. Wang CH, Wang CC, Huang HC, Wei YH. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. *FEBS J.* 2013;**280**(4):1039–50.
20. Sookoian S, Rosselli MS, Gemma C, Burgueno AL, Fernandez

Gianotti T, Castano GO, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. *Hepatology.* 2010;**52**(6):1992–2000.

21. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. *J Am Coll Cardiol.* 2010;**56**(14):1113–32.

22. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. *Endocrinol Metab Clin North Am.* 2004;**33**(2):351–75.